AU776673B2 - A synthetic peptide that disturbs intracellular signaling - Google Patents

Description

Regulation 3.2

AUSTRALIA

Patents Act 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT

(ORIGINAL)

r 1

I

,*i 4 4* *4444 *44*4 Name of Applicant: Actual Inventor(s): Address for Service: Yo ~mg-Tat COG d l nc.

Jeong Hyeok YOON, Young Tae HAN and Ky Young

LEE

DAVIES COLLISON CAVE, Patent Attorneys, 1 Little Collins Street, Melbourne, Victoria 3000.

Invention Title: "A synthetic peptide disturbing intracellular signaling." Details of Associated Provisional Application: No: PP 8643, 12 February 1999 The following statement is a full description of this invention, including the best method of performing it known to me: P W\OER\.1 A-d-'U\20 -2005 A- dn-1\2l6I01 5 po.w dom.6107/O4 A SYNTHETIC PEPTIDE DISTRUBING INTRACELLULAR SIGNALING BACKGROUND OF THE INVENTION The present invention relates to synthetic peptides from the motif which binds to src family protein kinase, and pharmaceutical compositions containing the same for treating cancer and immunosuppression.

Many of biological and physiological activation of a cell are controlled by external signals that stimulate or inhibit intracellular events. These events by which an external signal is transmitted into and within a cell to elicit an intracellular response are referred to as signal transduction. Intracellular signal transduction following the extracellular ligation of a wide variety of different types of extracellular factors (For example, hormones, adhesion molecules, cytokines, and the like) involves the activation of protein kinases. In order to activate these molecules, the receptor-target interactions are initially needed. These interactions stimulate a cascade to additional molecular interaction involving multipathways that transmit the signal events within the cells.

About 400 different protein kinases are known, and the number of total protein kinases will 20 more than likely double in the few years (Hardie G et al, (1995) The protein kinase Facts Book. London Academic). Many of the protein kinases involved in signal transduction consist of multiple domains, some of which have catalytic activity and some of which bind to other cellular proteins. The major area of primary sequence homology for the protein kinases lies within the catalytic domains, referred to as Src homology 1(SH1). The SH1 25 domains of the protein kinases can be further divided into 11 subdomains shared not only by enzymes but by all protein kinases. The next most common functional domains found are the Src homology 2(SH2) (Sadowski et al. (1986) Mol. Cell. Biol. 6:4396-4408) and Src homology 3(SH3) domains. SH2 and SH3 domains mediate protein-protein interaction in cellular signaling cascades, and are found in many proteins outside the Src family.

Extensive structural and functional studies of SH2 and SH3 domains in signal transduction have recently been described in three dimensional detail, that is pTy-binding (PTB) domains (P Blaikie et al., (1994) J. Biol. Chem 269:32 031: Zhou M et al., (1995) Nature 92, 7784-7788).

SH2 domains of approximately 100 amino acids are capable of high-affinrity binding to phosphotyrosine-contai ning peptide sequence that promotes protein modificationdependent protein-protein i nteraction (Pawson T et at, (1992) Cell. 70:694-704)- The subsequent discovery that SH-2 domains bind to specific phosphorylated lyrosine residues has proi tiC IUdi ng Ras GT'Pase-activating protein(GAP), phosphatidyl inositol 3'-kinase(PLK), anid phospholipase C-y(Cantley etal, (1991) Cell 64:281-320). And also, SH2 domains serve to localize these proteins to activated receptors and are implicated in the modulation of' enzymatic activity (O'Brien et al, (1990) Mo!. C'el. Bil 10:2855- 2862: Roussel el u. 199 1I) Pro. Nati. Acad. Sci. USA 89:10696- 10700- Rlucker et at, (1 992) EMB() J 11 :3469-3479).

Synthetic phosphopept ides based on SH2 domains have been found to block the binding of phosphatidyinositol 3-k'inase to the platelet-derived growth factor (PDGOF) receptor .15 (Bscobedo el al, (1991) Mo). Cell Biol. 11:1125-1132 Fanll el a, (1992) Nature 352:726-730). In addition, mutational studies hav hw htteS1 oan l phiospatidylinositol 3-kinase, Ras GAP and PLC-y recognize distinct phosphopeptide sequence in the IVDGlF receptor (Banti et al, (1992) Cell 69:413-423 Kazlauskas et at, (1990). Science 247:1 578-1581 (1992) Mot. Cell. Bil. 12:2534-2544).

Another common features among the protein kinases are the Src homology 3(SH3) domains. SF[3 domnains consisting of approximately 60 residues in length and bind to proline-rich peptide N-equences have consensus PXXP (whterein,. X is a hydrophobic amino acid such as lie, Leu, Pro, Met, Phe, Tyr) which possess a left-handed polyproline type 11 helix structure (Feng et al, (1994) Science 266:1241-1247). The association of Sf113 domain with polyproline helix also promotes protein-protein interactions and forms functional oligomeric complexes at defined Subcelluiar sites, frequently in conjunction with other modular domains (Pawson et al, (1995) Nature 373:573). Proteins can have multiple SH3 domains, potentially allowing clustering of several distinct ligarids. and Ser or Thr phosphorylation adjacent to the proline-rich ligand may influence SHI domain interactions (Chen el al, (1 996) Rio. Chem 271:6328). Interestingly. in certain case, SH3-ligand interactions may bc negativcly regulated by the phosporylation of a conserved tyrosine (Park I1 I e al, (1996) Immunity 4:515-525: Broorne MA et al, (1996) J Bilt. C"hem. 271:16, 798-806).

The ptyr-binding (PTB) domains of the Shc and insulin receptor substrate-I (IRS-i) protein4 recognize phosphopeptide motifs in which pTyr is preceded by residues that form a fi turn (usuitily withi the consensus NPXpY) (Ellaikie el (1994) DuO!. Chem.

269:32031). Specificity is conferred by hydrophobic amino acids that lie five to eight residues N1-1 2 -terminal to the pTyr (Trub et al, (1995)] J ioI. C'hem. 270:18205) and therefore recogniz their ligands in a distinct manmer to formn SI-2 domain (Thou ut a/, (1995) Nfalure 378:584). PITB domains may serve a somewhat dillerent role from SH2 domains, because they are found primarily as components of docking proteins that recruit additional signaling proteins to the vicinity of an activated receptor. The PTB domains of proteins such as Xli1, FE65, and Numb can bind nonphosphorylated peptide motifs, indicating that PTB domains are principally peptide recognition elements, unlike SH2 domains that appear devoted to the job of pTyr recognitio)n.

Piotein-protein interactions that are attractive as therapeutic targets Include the SH2 domtains of Syk fam~ily kinases which are essential for coupling with irmmune response receptors, the SH2 and SH3 domains of Src family kinases which are involved in coupling with receptors and downstream effectors, and the PTB3 domains which are.

essential for Shc functions. The challenges that remain to be 1met in developing Inhibitors of these domains include the need to identify compounds that Lire highly specific fir each protein, that demonstrate membrane permeability and high allinity, and possess the appropriate pharmac-okinetics and safety Profile.

Proiein-proteinii ineractions are involved in each and every step of intracellular signal transduction. 7ThuLs, at the plasma membrane, the signal is initiated in the cytoplasm by receptor recruitment of other cellular proteins; in the cytoplsm, the signals are dissiminated to different cellular location; and in the nucleus, the signals are transduced to other proteins involved in transcriptional control fromn complexes to regulate transcription of particular genes.

The Src-famnily nieMberS Nhare a common regulatory mechanism, but differ in cell-ular expression and localization. Nine Src-family tyrosine kinases have been identified (SrC, Lck. Hck. Fyn, F&gr, Yes, B3lk, Lyn, and Yrk) (Brown M (1996) Biochem Biophys Acla 1287, 121-149). The highly conserved regulatory apparatus of the Src family member consist of two peptidc binding modules the Src homology domains SH2 and SH-3.

These modules bind to targets containing phosphotyrosines and polyproline type Ti helices, respectively, and mediate the formation of protein-protein complexes during sialing. Accumiulating evidence suggests that selected sequence surrounding tyrosine phosphorylation site and polyproline rich site can be recognized by proteins containing SF-2 domains and SH3 domains, respectively, and that such protein-protein interaction functions to propagate intracellular signal by mediating the flunction and or dissolution of protein complexes. Phosphoprotein recognition by S112 doinain and polyproline recognition by SH3 are though to derive specificity from the presence of these domain properties as well as the surrounding amino acid sequence- Io The signaling phenomenon associated biologically or physiologically with cell proliferation can be regulated by inhibiting the protein-protein interaction using peptides which react with small regulatory domains. For example, intra- or extracellular signals which elicit the expression of genes associated with cell proliferation 15 and division is blocked not to be transmitted into nucleus, leading cell growth termination and consequently cell death.

Accordingly, the potential inhibitors of SF13 domains of proteins which are involved in coupling with receptors and transmission to downstream effectors should be met high specificity and high alinity for each protein and possess the appropriate pharmacokinetics and safety profiles.

The present inventors made researches to provide new peptides having high affinity to .SH-3 domains so as to inhibit protein-protein interactions in signaling pathway, and as a result thereof, they found that synthetic peptides comprising thu amino acid sequence (1) show high affinity to S113 domains, and that, if palmitic acid is coupled to N-terminal of Lhe peptide, the reSUlling peptides have an increased permeability into cells. The peptide and N-palmitoyl peptide may be advantageously employed flor treating cancer and iinmunie suppression-associated diseases.

Y0 SUMMARY OF THE INVENTION Thus. the present invention provides novel inhibitor peptides showing high affinity to SI13 domains and capable of disturbing or blocking intracellular signal pathway mediated by SH-3-ccintaining proteins, while possessing appropiate pharmacokinetics and safety profiles.

The present invention also provides a use of the peptides as agents tor treating cancer or rnmune suppression-assuclated diseases.

Tile present invention still provides pharmnaceutical composition for treating cancer or Immune sLuppression-associated diseases, which comprises the peptide of the present inventlion.

BRIEF DISCRIPTION OF THE DRAWINGS FIG. I Is a graph showing binding affinity the inhibitor peptides of the invention to SI B3Gs'r fusion. protein; FIG. 2 is. a fluorescent microscopy of translocation of palrnitoylated inhibitor peptides the cells; FIG. 3 is con focal microscopy showing distribution of palmiitoylated inhibitor peptides it.his cel roporesis showing the effect of palmitoylated inhibitor peptides on Lhe phosphorylation of tyrosine; ~PIG. 5 is an electrophoresis showing the effect of palmitoylated inhibitor peptides on the phosphorylatio n of components of signaling pathway; FIG. 6 is flowv cytornctry showing the effect of inhibitor peptides on the intracell-ular calcium concentration; 7 is a graph showing the effect of inhibitor peptides on cancer cell growth, which is measured by WTS analysis; and FIG. 8 is microscopic photos showing the changes in the number and shape of cancer cells treated with inhibitor peptides of the invention.

DETAILEDB DESCRIPTION OF TH-E INVENTION The synthetic peptides of' the present invention which are derived from the motifs binding to certain proteins, for example Src family kinases (hereinafter, referred to as "peptide" or "Inhibitor peptide"), have part or all of the amino acid sequence represented by the folIlowing formula

KXX

1

,X,,PX

4 XPXPX, (D) Wherein, K is Lys; P is Pro, Xis Arg. Asp or Lys; X, is Arg, Lys, Pro, Leu or Ile;

:X,

1 X, and are, identical Or different from each other, independently Pro, Met, Val, TIrp, Phe, lie or I .eu: X6 is Asn, Gin, Arg or Lys; X, is Asp, Glu, Arg or Lys; and wherein one of these armino acid residues may be conjugated to I or 4 amino acid residues, wherein in the case that one residue is con~jugated, the amino acid is Tyr, pI~yr(Phosphotyrosine), and that four residues are conjugated, the amino acids may be :Tyr or pTyr for thc first residue, Asp or Glu for the second and third residues, and hdrophobic amino acids such as le, Leu, Val or Met for the fOUrth residue.

The representative peptides having all or part of the sequence of the present invention may include SFQ. ID. Nis I through 12, which are indicated in Sequence Li~sting- The peptides of the present invention, which bind target protein within cells, are determined by in inh.) binding assay using GST-fusion protein expressing SH3. and deteriorate certain cells, e.g. cancer cells expressing Src family kinases.

The peptides according to the present invention may be manufactured chemically or by gene- recombi nati oi technology, and their -variants and derivatives produced by modification such as deletion, substitution and addition. They preferTably have 4 to 315 amino acid residues.

The phiarmaceutical composition containing the inhibitor peptides may be employed in the form. of solutions, micelles, liposome, or suspensions in an appropriate adjuvant.

The inhibitor peptide may be conjugated to lipid in order to enihance its tiranslocation into cells and targeting to cancer cells. In a preferred embodiment. the pepfide may be conjugated with mono- or di-palmitic acids to its N-terminal lysine.

The pharmaceutical composition according to the present invention mlay be administered to human via, parenteral or local routes, and prellerubly in the form of I0 solution or suspension in aqueous vehicles.

The inhibitor peptides may be employed for antitumor treatmecnt for hepatoceliular ***carcinoma and other cancers which express SH3 domains, as well as to suppress the metastasis of' cancer cells after clinical surgery in cancer patients.

g~e D~efinition of Termi Throughout the specilication and claims, the terms have the [iollowi ng mneaninlgs: The termi "peptide" is used interchangeably with "oligopeptide" in the present specification to designate a series of residues, connected onc to the other typically by peptide bonds between the alpha-aimino and carbonyl groups of adjacent aino acids.

*Felength of oligopeptides is not critical to the invention so long as the correct sequences are maintained. The peptides are typically less then about 50 residues in length, except for repeatedly conjugated forms (example for S112-SH2-SH2 n, SH3- SH-3-SH3--n), and usually consist of between about 4 and about 20 residues, preferably 13 or 16 residues.

"Inhibitor peptides" are peptides which comprise SI-2 anid SH3 binding domains such that the peptide will bind the intracellular proteins contained these domains and be capable of blocking or disturbing signal pathway events. Thus, in a variantl of' cancer cell, inhibitor peptidcs arc capable of binding to an appropriate intracellular protein Such as protein kinase and signal adoptive protein which are related with signal pathway for is dhe cell pro11ieration and division.

P %DPERkjC A. nold', 1101 1Q004 2005 A~lCdsol1\226857 -Pon0- dm.I/0O.

The term "palmitoylated-peptide" refers to the pattern of lipid (palmitic acid)-conjugated inhibitor peptide. The palmitoylation is designated to enhance the translocation of inhibitor peptides into the cells and the targeting cancer in vivo.

The "cancer" includes a variant of human/animal cancers that express intracellular proteins containing SH2, SH3 and PTB domains.

Moreover, three letter codes are used to indicate amino acid residues according to WIPO Standard ST.25(1998), Appendix 2, Table 3.

Free Texts in Sequence Listing SEQ. ID. NO. 1 SEQ. ID. NO. 12 Peptide which specifically binds to SH3 domain with high affinity, thus inhibiting intracellular signal transmission.

SEQ. ID. NO. 13 Comparative peptide 20 The present invention will be described in more detail below.

The present invention provides peptides capable of inhibiting signal transduction pathway in cancer. The subdomains of inhibitor peptides are originated from the multi-domains of proteins binding to particular proteins such as Src family kinases, and show high affinity to SH3 domains so that can be used to regress/reject cancer cells by inhibiting intracellular signal pathway mediated by SH3 domains.

The peptides of the invention can be prepared synthetically or by recombinant DNA technology. Although the domains comprising inventive peptides will preferably be 30 substantially free of other naturally occurring host cell and cancer cell, such as oo*• lymphocytes and a variety of cancer cells, other host cells, proteins and fragments thereof, in some embodiments the peptides can be synthetically conjugated to native fragments of particles. The peptides may be prepared by recombinant DNA technology in which expression vectors into which DNA having DNA sequence coding for the peptide is incorporated are employed. Such vectors can he constructed so as to be transferred to cancer-inducing loci, transfected into an appropriate host and then expressed Linder proper conditions according to the methods described by Sambrook el al. (Molecular Cloning, 1989, Cold Spring Harbor, Cold Spring Harbor Laboratory PreSS). Moree, the peptides may be prepared from fusion proteins containing one or miore peptide fragm-ents of the invention.

As the coding sequence for peptides of the length contemplated herein can be synthesized by chemical techniques, for examnple, the phosphotriester method of Matteueei et al., Ami. CThem. Soc. 103:3 185 (1981), modificationi can be inade simply by substituting the appropriate base for those encoding the native peptide sequence. The coding sequence can then be provided with appropriate linkers and ligated into expression vectors commonly available in the art, and the vectors used to suitable host V. to produce the desired ftision protein. A niumber of such vectors and suitable host system are 110w availabie. for expression of the fusion proteins or polypeptides, the coding sequenc wil be provided with operably linked start and stop codons, promnoter and terminator regions and usually a replication system to provide an expression vector for expression in the desired cellular host.

201 The polypeptides Or peptides can be of a variety of lengths, either in their neutral :(uncharged) rornis or in fonns which are salts. They may be free of any modifications, or mnay be subject to modifications such as glycosylation, side chain oxidation, or phosphorylation as long as their biological activity retains. The peptides have a length of' about 50 amino acid residues or less, preferably 4 to 20 amino acid residues, and miost preferably 8 to 16 amiuno acid residues.

[he in vivo activity of the inventive peptides comprising the domnains involved in intracellular signaling cascades can be increased by modification such as lipidation, glycosylatiori or conjugation to other peptides. For instance, a covalentl attachment of lipid chains such as palmitic acid to peptides will increase intracelltular translocation and Cancer targeting by the affinity with lipid. In addition, the use of' cancer or specific organ targeting vector/viral vector, which are encoding to these inventor forms, can also be applied the same Purpose. The lipids, which may be conj ugated to the pcptide of the invention in order to increase the translocation of the peptide into cells by enhancing the affiniity with cell membrane lipids, may include Cig saturated futty acids, Or C 1 6 or C,, P 1OPE scWdniO11W004 200 A,,,d-sot\2260837 im do. -6fO7/I0 unsaturated fatty acids.

The peptides can also be modified by extending or decreasing its amino acid residues, for example by the addition or deletion of amino acids. The peptides of the invention can also be modified by altering the order or composition of certain residues as long as such modification does not affect the activity of the peptide. Those of ordinary skill in the art to which the present invention pertain readily appreciate that the amino acid residues ("critical amino acids")essential for biological inhibitory activity, for example those at critical contact sites or conserved residues, are not subject to such alteration to retain their inhibitory activity. The non-critical amino acids need not be limited to those naturally occurring in proteins, such as L-a-amino acids as well, such as 3, y, 6 amino acids, as well as many derivatives of L-a-amino acids.

Typically, a series of peptides with single amino acid substitutions are employed to determine the effect of electrostatic charge, hydrophobicity, etc, on binding. For instance, a series of positively charged Lys or Arg) or negatively charged Glu) amino acid substitutions are made along the length of the peptide revealing different patterns of sensitivity towards intracellular kinases/adopter proteins containing signaling modules SH2 or SH3. The number and types of residues which are substituted or added depend on the spacing necessary between essentially contact points and certain functional attributes which are sough hydrophobicity versus hydrophilicity). Increased binding affinity for a appropriated intracellular target proteins involved in signal pathway may also be achieved by such substitutions, compared to the affinity of the intact peptides of the ""invention. In any event, such substitutions should employ amino acid residues or other molecular fragments chosen to avoid, for example, steric and charge interference which 25 might disrupt binding.

••go Amino acid substitution is typically of single residue. Substitutions, deletions, insertions or oo any combination thereof may combined to activate a final peptide. Substitutional variants are those in which at least one residue of a peptide has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Table 1 when it is desired to finely modulate the characteristics of the peptide.

TABLE 1 Suitable residues for amino acid substitutions Original residues Exemplary Subsiti tuti ons Ala Ser ArS Lys Asn Gi1n: His Asp Glu Cys Ser Gin Asn.

oG-lu Asp Gly Pro Hius Asn: Glu e Leu: Val Leu le: Val isLys Arg: Gin: Glu Met Leu: le Phe Met: Leu: Tyr *Ser Thr T hr Ser Trrp Tyr Trp: Phe Vat le: Leu Sbtiuioa alterations cause a significant change in the funictions of the proteins, for example the affinity to-ward kinases or adoptor proteins. Substitution may produce a big impact on the Structure of the peptide backbone, for example as a sheet or helical conformation, the charge or hydrophobicity of the molecule at the target site or the bulkiness of the side chain. The substitutions which in general are expected to produce the greatest changes in peptide properties will be those in which a hydrophilic residue, e.g. seryl, is substituted for a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; a residue having an electropositive side chain, e.g. lysyl, atrginyl, or histidyl is subsrituted for an electronegative residue, e.g. glu~tamyl Or aspartyl; or a residue having a bulky side chain is substituted for one not having a side chain, e.g.

glycine P.%OPER~jicNAAitldaido.112004-2D5Ao sedisO-2260957 pOsac doC.l 'O6710 All the peptides in which one or several amino acids are substituted with D-amino acids, or with amino acid derivatives such as hydroxyproline, hydroxylysine, cystine, thyroxine, norleucine or pyroglutamic acid, or with methylated amino acids, are encompassed within the scope of the present invention. Moreover, the peptides which have C-terminal of an amide, a carboxyl or an ester also fall in the scope of the present invention as long as they can accomplish the object of the invention.

The peptides of the present invention may also comprise isosteres of two or more residues.

An isostere as defined here is a sequence of two or more residues that can be substituted for a second sequence due to the steric conformation of the first sequence. The term specifically includes peptide backbone modifications well known to those skilled in the art.

Such modifications include modifications of the amide nitrogen, the ca-carbon, amide carbonyl, complete replacement of the amide bond, extensions, deletions or backbone crosslinks.

Modification of peptides with various amino acid mimetics of unnatural amino acids are particularly useful in increasing the in vivo stability of the peptide. Stability can be assayed in a number of ways. For instance, peptidase and various biological media, such as human plasma and serum, have been used to determine stability.

S* The present invention also provides pharmaceutical compositions containing one or more peptides of the invention as active ingredients.

In some embodiments it may be desirable to include in the pharmaceutical compositions of •the invention at least one component which assists the intracellular translocation and cancer targeting using peptide-lipidation method. Lipids have been identified as agents capable of assisting the intracellular translocation and partially cancer targeting. For example, palmitic acid residues can be attached to the alpha and epsilon amino groups of 25 Lys residues and then linked, e.g. via one or more linking residues such as Gly, Gly-Gly, Ser or Ser-Ser. The lipidated peptide can then be injected directly in the form of micelle, or incorporated into a liposome or emulsified in an adjuvant, e.g. incomplete Freund's adjuvant. In a preferred embodiment, a particularly effective translocation and targeting comprises palmitic acid attached to alpha or epsilon amino groups of Lys. Inhibitor peptides of the invention can be coupled, for example to Pal2K (Palmityl- 12- Palmnityl-Lsy) or PaI1,CK(Pal mityl- Palmityl -PalrnitylI-Cys -Lys), and the resulting lipopeptides can be administrated to the subject to specifically inhibit cancer growth.

For targeting to the cancer cells, the peptides may be incorporated into the liposome which contains antihu~dy or* its fragments specific for cell surface determinants on the target cancer cells.

For solid JirrnulatiOnlS, pharmaceutically acceptable conventional nontoxic solid carriers may be used. Such carriers may include, but not limited to, mannitol, lactose, starch, 0 magnesium stearate, sodium saccharin, talcum, cellulose, glucose, SaLcrOs:e, magnesium carbonate, and the like. For oral administration, 10-95% by weight, and more preferably 25%-75%X by weight based on the total weight of the timulation of one or more peptides of' the invention ais active ingredients are incorporated into the above listed carriers to give oral formoulations.

The pharmaceutical composition of the present invention mnay also be administered into the subject by parenteral or local route, for example intravenous, subcutaneous, intracutancous, intramnuscular route and the like- For aerosol administration, the peptides of the present invention are preferably supplied :in finely divided form along with a surfactant and propellant. Typical amiount of *peptides is 0.0 by weight, and preferably Il%-l10% by weight based on the total weight of the formulation.

The amount of the composition of the present invention to he administered is not liited to certain rangc, arid may be determined by those of skilled in the art without difficulty depending on the severity, condition, age and body weight of the patient. But, it is generally in the range of about 5 100 mg/kg/day, particularly about 10 mig/kg/day, and preferably about The peptides or pharmaceutical composition containing tile same may show physiological activity in living body and its physiological activity may be measured in Viw,) inl blood or bone marrow samples from patients administered with the peptides or compos iions.

P NO PERajlc~s%-%dn3-s%2DO042OO0 Atnodniatts%22605I7 -p-c dmI16/O07/O.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.

The present invention will be described in more detail by way of representative working examples, but should not be construed to limit in any way the scope of the present invention.

EXAMPLES

Example 1 Peptide synthesis Inhibitor peptides (SEQ ID NO: 1) was synthesized by solid-phase peptide synthesis using the Applied Biosystems 430 A synthesizer, our own Fmoc program and Fmoc L-amino o* 15 acids from Novabiochem (Laufelfingen, Switzerland) with side-chain-protecting groups: Lys (Boc), Arg (Mtr), Asp (OtBu), Tyr (tBu).

Starting each synthesis with 1 g p-benzyloxybenzylalcohol-resin loaded with either Fmoc- Asp-OH (0.35 mmol) or Fmoc-Arg-OH (0.35 mmol) the following synthetic cycles were carried out: Na-deprotection with 55% piperidine in N-methylpyrrolidone (1x2 min, 20 min); preactivation of Fmoc-AA-OH (1.5 mmol) in N-methylpyrrolidone (6 ml) with o diisopropylcarbodiimide (1.5 mmol) and 1-hydroxybenxotriazole (1.5 mmol) followed by coupling for 1.5 hours. After washing with N-ethylmorpholine in Nmethylpyrrolidone), preactivation and coupling were repeated. Capping of non-reacted amino groups was performed with acetic anhydride (2.5 mmol) and diisopropylethyamine (1.2 mmol) in N-methylpyrrolidone. Having synthesized the resin-bound peptides, analytical peptide probes were removed by trifluoroacetolytic cleavage and checked by high performance liquid chromatography, FAB mass spectrometry amino acid analysis.

-14- P O0PER~jc',,\A.,d,I,\2004.2003 A-,dno.2260657m do 16JO7104 The same procedure was repeated to synthesis the peptides of SEQ. ID. NO. 2 through SEQ. ID. NO. 12.

Example 2 Lipidation Peptide-conjugated resin (SEQ. ID. NO. 1) and palmitic acid were coupled in benzotriazole N-methylmorpho line and added in a fivefold excess to the peptide resins. After 3 hours, the lipopeptide-resin was washed with methanol (3 14a P.%OPERxjtc AiticdlloN00 k20OA-2005 A6c d ts\2261 rnpOssc doc. 67I/0 times) and couplings were shown to be complete to 99% by the ninhydrin test. The less coupled peptide was double-coupled using a fivefold excess in benzotriazole-1-yl-oxy-trispyrrolidino-phosphonium hexafluorophosphate N-hydroxybenzotriazole

N-

methylmorpholine for about 14 hours. The lipopeptides were removed from the resin in trifluoroacetic acid (4 ml) containing thioanisol (250 jil) and ethanedithiol (150 p1l) within 4 h. The filtrate was evaporated the residue taken up in acetic acid and poured into stirred cold ether. The precipitated lipopeptide was washed three times with ether. Further purification was achieved by precipitation from trifluoroethanol/chloroform (3 ml) with cold acetone (20 ml) followed by addition of a few drops of water. The lipopeptides were lyophilized from t-butanol/water Amino acid analysis and FAB-mass spectrometry proved the identity of the lipopeptides each having palmitoyl-palmitoyl at the N-terminal lysine of the peptides of SEQ. ID. NO. 1 through SEQ. ID. NO. 12.

Reference Example Preparation of GST fusion proteins In order to assess the inhibitory activity of the present peptides, the ability of the inhibitor peptides to inhibit the interaction between a specific peptide motif and SH3 domain was determined. Various SH2 and SH3 domains were subcloned in frame with the pGEX vector system (Pharmarcia). The resulting pGEX-E2 construct encoded a glutathione-Stransferase (GST)/SH2 and glutathione-S-transferase (GST)/SH3 fusion protein. The pGEX construct was introduced into E.coli by transformation, and the transformation grown in liquid media (LB) in the presence of IPTG. Purification of GST/E2 fusion protein .was by standard protocols (Current Protocols in Molecular Biology, eds. Ausubel et. al., (NY:John Wiley and Sons, 1991). Briefly, the cells were pelleted and resuspended in buffer A (50 mM TRIS (pH7.5), 2 mM EDTA, 250 mM NaCI, 5% glycerol 1% Tween 25 1% Triton X-100 to which 2 mM PMSF and 15 mM 2-mercaptoethanol were added. Bacteria were mechanically disrupted by sonication or by microfluidizer, and the soluble fraction of the lysate was absorbed with glutathione-agrose beads which had been rehydrated in buffer A. Absorption was for 30 min to 14 hr at 4 0 C during which the beads were maintained in suspension by rocking. Subsequently, the beads were washed 3 times in cold buffer A followed by 5 washes in 50 mM Tris, pH Experimental Example 1 Measurement of binding of peptides to SH3 domains P O0PER cA ,uoldn oats%-' OD4.205 A "iscaoit s oC I/O)67: To assess the ability of the peptides prepared in Examples 1 and 2 to bind to SH3 domains, the peptide SEQ. ID. NO. 1) and its palmitoylated product were coupled to aminomethyl coumarine acetate ("AMCA").

Each peptide 5 mg and AMCA were dissolved into Iml of 50 mM sodium bicarbonate buffer (pH and 5 mg/ml dimethylsulfoxide (DMSO) was added thereto just before starting reaction. 50 100 pl of AMCA was gradually added to the reaction mixture while stirring or agitation, and the resulting mixture was allowed to react at 4 0 C for a day with continuous stirring. After reaction, peptides coupled to AMCA were separated from nonreacted AMCA by gel filtration.

Then, the AMCA-peptide complex (0.075-1.4pM) was reacted with 3.12 atM GST/SH3 fusion protein, and the reaction mixture was allowed to stand at room temperature for 1 minute. The binding affinity between the peptide of the AMCA-peptide complex and SH3 domain of GST/SH3 fusion protein by using resonance energy transfer method and double laser spectrofluorometry (PTL-3965, Japan). This method is based on the phenomenon that the peptide bound to AMCA emits fluorescence at 350-450 nm. The relative transfer efficiencies were determined as follows the sample containing the GST/SH3 fusion protein and peptide-AMCA complex was irradiated at 280 nm to excite tryptophan of GST- 20 SH3 fusion protein with irradiation at 280 nm, and AMCA-peptide complex was excited by the emission of 350nm by the excited tryptophan to emit 450 nm fluorescence.

As result, when the peptide is bound to AMCA and then to SH3 domain of GST fusion protein, the 350 nm fluorescence of tryptophan by 280 nm emission reduces while the 450 nm fluorescence of AMCA coupled to the peptide increases (FIG It can be explained that the peptide of the complex binds to GST/SH3 fusion protein to absorb the fluorescence emission wavelength of 350 nm produced by tryptophan of GST/SH3 fusion protein, thus making it possible for peptide of the complex to emit 450 nm fluorescence.

S 30 The 450 nm fluorescence emission of AMCA increases proportionally and the 350 nm fluorescence emission of tryptophan decreases depending on the amount of the peptide of the complex, while 450 nm fluorescence of GST/SH3 fusion protein does not show 16- P,%OPER(\rck~nlldm.1VsD( 004. A -,a22603S7 I do. 1610710 such dependency. It consequently means that the peptides of Examples 1 and 2 have high affinity to SH3 domain.

Experimental Example 2 Detection of translocation of inhibitor peptides into cells In order to determine whether the above palmitoylated inhibition peptides could be translocated into intracellular regions, Jurkat cells treated with the FITC-conjugated palmitoylated inhibition peptides were observed under a fluorescence microscope.

Specifically, palmitoylated inhibition peptides were conjugated with FITC using the standard procedure, and the Jurkat cells were incubated for 5 hours in 12-well plate containing 5-100pg/ml of the FITC-conjugated palmitoylated inhibition peptides, then the treated cells were positioned on microscope slides, and fixed by adding a fixing solution.

Finally, the fluorescence from the translocated FITC-conjugated peptides was observed by fluorescence microscopy with 400-fold magnification. As a result, fluorescence light from the FITC-conjugated inhibition peptides was detected in the intracellular region of cells treated with 50pg/ml. These results indicate that palmitoylated inhibition peptides can be translocated effectively into the intracellular region (see, Figure 2).

Experimental Example 3 Analysis of the. intracellular distribution pattern of the translocated peptides oo Although translocation of palmitoylated inhibition peptides into the intracellular region 20 was demonstrated in Experimental Example 2, the precise distribution of inhibition O. peptides in cells could not be identified. Therefore, intracellular distribution of the inhibition peptides was analyzed by confocal microscopy. Specifically, the Jurkat cells were treated with FITC-conjugated palmitoylated inhibition peptides as in Experimental Example 2, and the treated cells were subjected to five washings with buffer. After washing, the cells were positioned on microscope slides, and fixed by adding a fixing solution. Finally, the fluorescence distribution in the cells was observed by confocal microscopy.

As a result, it was confirmed that the inhibition peptides were translocated into the cells and that most inhibition peptides were distributed over the cytoplasm and near the nucleaus (See, Figure 3).

17- P NOPERIyckAnI adcocs\2OO.4.20 Anicdnioc\2260857 gspo.c d"-16107104 Experimental Example 4 Measurement of the inhibition effect on phosphorylation of intracellular proteins In order to test whether palmitoylated peptides can modulate intracellular signal pathway, their effects on signal pathway mediated by T cell receptor was measured. The TCR-mediated signal pathway is activated by phosphorylation of CD3 and r ITAM(Immunoreceptor Tyrosine based Activation Motifs)s by Src kinase such as Lck and then the phosphorylated CD3 and C ITAMs react with ZAP-70 to phosphorylate tyrosine of A mixture of Jurkat cell and inventive peptide (palmitoylated peptide SEQ. ID. NO. 1; "LP palmitoylated or non-palmitoylated comparative peptide (SEQ. ID.

NO. 13 was incubated at 37 0 C for 12 hours. The cell lysate was subjected to blotting using antibody against phophotyrosine.

As result shown in FIG. 4, for the LPI treated group, phosphorylation of tyrosine within cells drastically decreases at 100 pg/ml or 400 lig/ml of LP1 (lane b and lane c in FIG. 4B), while the LPc- or Pc-treated groups show basic level of phosphorylation. FIG. 4A shows the result when the concentration of LP1 is varied between 2 pig/ml and 200 pig/ml for the incubation of 6 hours. The tyrosine phosphorylation decreases at the concentration of 100 pg/ml (lane c and lane d in FIG. 4A), and drastically decreases at the concentration of about 200 pg/ml (lane 3 in FIG. 4A).

These results prove that the peptides of the present invention can effectively inhibit the early stage of signal pathway initiated by tyrosine phosphorylation. In addition, even though not depicted in Figure, the palmitoylated peptide (LPl) shows higher inhibitory effect on the tyrosine phosphorylation than non-palmitoylated peptide, suggesting that the palmitoylation can enhance the translocation efficiency of peptide into cells.

25 Experimental Example 5 Analysis of effect of peptide on phosphorylation of components of signal pathway As can be seen from the results of Experimental Example 2, it is believed that the 17a- P %OPER\j c~iSdni nit \2004 2005 A, Jaso sQ264095 I eoow d- I WO 7 04 palmitoylated peptide of the present invention inhibit the components involved in the early stage of signal pathway induced by cytoplasmic phosphotyrosine. Among the various early stage phenomena associated with signal pathway of T cells such as Jurkat cell, tyrosine phosphorylation is modulated by Src family kninase such as Lck or Fyn, while dephospohorylation is modulated by protein tyrosine phosphatase. Then, crosslinking of TCR in T cell and CD3 phosphorylation by Src kinase occur, and the phosphorylated CD3 complements ZAP-70. ZAP-70 binds to phosphorylated ITAMs in CD3 chain and Zeta chain to accelerate the accumulation of phosphorylated Zeta chain as well as to block dephosphorylation by tyrosine phosphatase. Accordingly, the inhibition of Zeta chain phosphorylation by LPI is accomplished by directly blocking Lck function or indirectly blocking the binding of ZAP-70 to phosphorylated ITAMs. Thus, the effect of LPI or Pc can be determined by measuring the degree of phosphorylation of Lck, ZAP-70, CD3 or Zeta.

Jurkat cell was treated with 50 (tg/ml or 300 [tg/ml of palmitoylated peptide for 6 hours and then suspended in a buffer containing leupeptin, aprotinin, phosphatase inhibitor (2 mM sodium orthovanadate, 0.4 mM EDTA, 10 mM sodium fluride and 10 mM sodium pyrophsphate), 50 mM TRIS-hydrochloride (pH 300 mM sodium chloride and Triton X-100. Cell lysate was subjected to electrophoresis on SDS-polyacryl amide gel (4- 20% SDS-PAGE) and then transferred to nitrocellulose membrane.

20 Nitrocellulose membrane was treated with 4% skim milk in PBS buffer and subjected to *immunoblotting using the antibody indicated below to evaluate the expression at protein level. As antibody, clone 4G10 anti-phophotyrosine antibody (Update), antibody (Transduction Laboratories), anti-Lck antibody (Santa Cruz) or anti-Zeta() chanin antibody (Santa Cruz), which was diluted to 1:1000, 1:1000, 1:1000 or 1:500 25 respectively, and secondary antibody coupled to HRPO (Amersham) in 1:2000 dilution were employed.

As result, Lck kinase activity was significantly reduced by LP1, but not by LPc or Pc (FIG In FIG. 5, the terms of"LP1", "LPc" and "Pc" have the same meaning as defined above in FIG. 4, and indicates for control group. The phosphorylation of CD3 Zeta also was significantly reduced by LP1, indicating that the phosphorylation of CD3 Zeta was influenced negatively by the decrease in the Lck kinase activity.

18- P.IOPER~pcAmoladoilrU s)1DM 4 2005 Ancd-,Ius\22605 mp- do1I67101 The inhibitory effect of LPI is even stronger on ZAP-70. The inhibition of phosphorylation causes a change in dynamics of phosphorylation, and in particular, the inhibitory action on Lck-induced ZAP-70 phsophorylation was strongest when the concentration of LP1 was 200 jag/ml or more. Thus, it can be found that LP1 blocks the early stage signal pathway in Jurkat cells by inhibiting Src kinase, and it shows strongest inhibition when applied to a concentration of about 200 jpg/ml or more per 1 x 106 cells.

Experimental Example 6 Analysis of effect on intracellular Ca transport As can be seen from Experimental Example 3, peptides of the present invention inhibit phosphorylation of Lck and other related proteins, which eventually influences the late stage phenomena of signal pathway such as calcium ion transport within cell.

In order to determine whether the peptides of the present invention inhibit the late stage of signal pathway, Jurkat cells were treated with LPI (100 pag/ml) at 37 0 C for 1 hour (FIG.

6B), other peptides (FIG. 6C) or buffer only (FIG. 6A). The treated cells were resuspended in PRMI1640 medium supplemented with 3 mM Fluo-3AM to a concentration of 5 x 106 cells/ml and then incubated at 37 0 C for 30 minutes. The cells were washed with ice-cold LOCKS buffer (150 mM sodium chloride, 1 mM magnesium sulfate, 5 mM potassium chloride, 10 mM glycine, 15 mM HEPES, pH 7.4) and then resuspended in the same buffer S: to a final concentration of 1 x 106 cells/ml. Thus-treated cells were preserved on ice in the dark before use. For flow cytometric analysis, cells were heated to 37 0 C for 5 minutes, and the calcium level before and after addition of anti-CD3 antibody (OKT3) was measured by FACScalibur (Becton-Dickinson, San Jose, CA) (FIG. 6).

As result, for the group treated with LPI, the outflow of calcium ion which follows the stimulation ofTCR by OKT3 does not occur, while LP1 treatment does not influence the calcium ion inflow induced by ionomycin. This facts indicate that the peptide of the 30 present invention influences the downstream of signal pathway such as intracellular calcium ion level in TCR-mediated signal pathway.

Experimental Example 7 Anticancer activity Measurement of cell growth with MTS assay.

19- P I W07_00-Mi *111101r~~s C)~lY00 lb010' To test anticancer effect in vitro, human hepatocellular carcinoma (SNU-398)(Park J G et al (1995) Int. J. Cancer 62:276-282) was obtained from Korea Cell Line Bank (Korea).

Hepatocelluar carcinoma (HCC) was maintained in culture using RPMI-1640 (Sigma) medium (Gibco BRL) and 5 x 10 5 M 2-mercaptoethanol (Sigma).

SNU-398 cells (5 x 105 cell/well) were plated in a 96 well plate. Assay medium consisted of RPMI-1640 (Sigma) contained 10% FBS (Gibco BRL), 4 mM L-glutamine (Sigma), gentamicin (Gibo BRL) and 5 x 10- 5 M 2-mercaptoethanol (Sigma). Palmitoylated inhibitor peptides (LPI and LP2) were treated with varying concentration and then incubated for 24 hours in CO 2 incubator at 37 0 C. Then 20 pil/well of CellTiter 96® AQueous solution reagent (Promega) were added. After 1-2 hour at 37 0 C incubator in a 5% CO 2 the absorbance at 490nm was recorded using an ELISA plate reader(Bio-Rad). Each point represents the mean±SD of 3 replicates. The background absorbance shown at zero cells/well was subtracted from these data.

For comparison, the same experiments were carried out by using the comparative peptide SEQ. ID. NO. 13) and palmitoylated Pc("LPc").

20 The growth of cancer cell treated with LP1 was significantly decreased, and in particular ee began to show decrease at 30 ug dose and reach the maximum decrease at 160 pg dose where the cell was reduced to 1/4 of its original number (FIG. FIG. 8 is the microscopy of the cell growth change with peptide treatments, which shows that the LPI treatment (8A) induces a significant decrease in the density of cancer cells and morphological change 25 of cancer cells, while control Pc treatment (8B) and LPc treatment (8C) show no or only insignificant changes. The cancer cells treated with LP1 reduced in their size and lost adherence to the plate.

The above results suggest that the inhibitor peptides of the present invention show 30 potential inhibitory effect on the proteins having SH3 domains, which are involved in signal transduction associated with mitosis as well as signaling associated with Lck and the like. Accordingly, the peptides of the invention can be effectively employed as anticancer agents.

OTHER RE FERENC ES Volpina et al., Vaccine 14:1375-1380 (Oct., 1996). "Synthetic vaccine against lbot-and-niouth disease based on a palmitoyl derivative of the VP1I protein" Frwikenburg. et al., Vaccine 14:923-929 (Jun., 1996), "Effective immunication of mice against cutitrious leishrnaniasis using an intrinsically adj. uvanted synthetic I ipopeptide vaccine" Deprez. et al., Vaccine 14:375-382 (Apr., 1996), "Comparative efficiency of simple Ilipopeptide constructs 1101 in vivo induction of virus-specific CT1L" Babui. J. et al., Vac~cine 13:1669-1676 (Dec, 1995), "Primning for virus-specific CD8*t but not CD4-I- cytotoxic T lymphocytes with synthetic lipopteptide is influenced by :15I acylation units and liposome encapsulation" Sauzet. J. et al., Vaccine 13:1339-1345 (Oct, 1995), "Long-lasting anti-viral cytotox ic T lymphocytes induced in vivo with chimeric-mul ti restricted lipopeptides" 26 Rouaix. et al., Vaccine 12:1209-1214 (Oct, 1994), "Effect of a lipopeptidic :formulation on macrophiage activation and peptide presentation to T cells" Celis. et al., P.N.A.S. (USA) 91:2105-2109 (Mar., 1994), "Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary culture and synthetic peptide epitopes" Pawvson. et al., Cell. 70:694-704 (1992), "SI-f2 and S1 13 domain&: from structure to function" 341 Feng. et al., Science 266:1241-47 (1994), "Two binding orientations for peptidles to the Src S) 13 domain: development of a general model for SI-3 ligand interactions" B~urke. T. R .,et al., Drugs of the Future 17:119-31 (1992). "Protein-tyrosine kinase inhibitors" Tsuruga. et al., Chern. Pharrr. Bull. (Tokyo) 39:3276-8 (1991) Biologically active constitiuent~s fo Melaleuca leucadendron: inhibitors of induced histamine release from rat mast cells" .1 Hanke. I. et al., B~iol. Chern. 271:697-701 (1996) "Discovery of a novel, potent, and Src fam ily selecti-ve tyrosine kiase inhibitor" ihu.Q., et al., J. Lxp. Med. 180:461-70 (1994), "Deletion within thle Sue homology domain 3 of Bruton's tyrosine kinase resulting in X-linkcd aganunaglobulinlemia 0 (XLA)" Rickles. R. et al., P.N.A.S (USA) 92:10, 909-13 (1995), "Phage display selection of ligand residues important 16r Stc homology 3 domain binding specifiety" eng. et al., P.N.A.S (UISA) 92:12,408-15 (1995), "Speci fie interactions outside the :15i proline-rich core of two classes of Src homology 3 ligands" EDITORIAL NOTE APPLICATION NUMBER 16384/2000 The following Sequence Listing pages 1 to 6 are part of the description. The claims pages follow on pages 23 to 24.

1- [Sequence Listing] <110> HAN, Young T 'i <120> A synthetic pept-ide distrubing intracellular signal ing 130> PAU-000212 <160 13 <170> Iatent in 2.1 <210> 1 <211> <212> <213> <22(0> <223> inhibiti <400> L.ys Glu

I

11 PRTr Artificial Sequence Peptidc which specifically binds to SH3 domain with high affinity, thus ng intr;crl lular signal transmission Arg Pro Pro Pro Val Pro Asn Pro Asp 5 <210> 2 211:> 11 <212> PIN <213> Nrtificial Sequence '<220> <223> Peptide which specifically binds to SH3 domain with high affinity, thus inhibiting in(rarellular signal transmission <400O> L~ys Arg 1 <2 <21l> <212> <213> 2 pr-o I.jtu Pro Pro Leu Pro Asn Pro Asp J

PRT

Artifici;lI Scqtience <c220> inhihi pep( icYj whlich .jpeci fiLcal ly binds to S113 domain wi th high aff ini thus unIg 11I';rWVhhcl~IJC Sign-Il transmission .r400> 3~ Lys ALrg Pro Pro Pro Pro Leu Pro Asn Pro Asp 1 <21.0> <212> <2 13> <220> -223> i nh b 1)i 4 1. 1

PRT

Fepiae which specifically binds to S3 domain with high ogffiriity, thus ir-ig inLIiaCelI:' signal transmissbion <400> <2131> <212> 4 Ar-g Pro Pr'o Pro Leu Pro Asn Pro Asp 11

PIRT

<213> Ar t if Ii aI Sefltice <223> Pe.pi ide which specifically binds S113 domain wilh high affinity. Otis inhibitijng Ini-rm-el lular signal1 transmission <400> Lys Glu Arg Pro0 Pro Pro Tyr Pro Asn Pro Asp 1 5 6 O~*<211> 11 <212> PlRT 1: Artificinl eece 220> <223> Peptide~l wIcIh specifically binds to SH:3 domaini with high affinity. thus i inhibI)it irig intriaci Itilr signal transmission 400> fi Lys Leu LeU Pro Pro Pro Leti Pro Asn Pro Asp 1 5) *<210> 7 <,2)11 Li (212> P Kk <213>S Artificid SO(Iuence 220(> Peptide which specifically binds to SH3 domnain with high Oif iiiity. thus inhibiting jntracel lular signal transmission <400> 7 Lys Arg Pro Lceu Pro Fro l.eu Pro Leu Pro Asp 1 5 -4- <210> <211> -<212> <213> 8 11

PRT

Artificial Sequence <:220> <223> Peptide which specifically binds to SH3 domain with high affinity. thus inhibiting intracellular signal transmission <400> Lys (;1G

I

8 Arg Pro Pr, L.cu Pro Pro Asn Pro Asp .5 0* 6oo 0 0 <210> <211> <212> <213> Art ificial Sequence 9@ 9 0 @9 .9 0909 9 *0@e c220> <223> Peplide which specifically binds to SH3 domain with high affinity, thus inhibiting intracel lular signal transmission <400> 9 Lys Arg Pro Pro Pro Pro I.eu Pro Asn Pro Asp 1 <210> <211> <212> <213> <220> <223> 1(1

P'RT

Artificial Sequence Peptide which specifically binds to SH3 domain with high affinity. thus inhibi t ing intr~icel lukir signal transmission <400> Lys GlIu

I

Arg Pr-o Pro Pro Val Pro Ain Pro Asp J <21 1> <2 12> <213> 11

PVT

S

0O59 0@SO

S@

S S

SS

SS *S S S

S

S@

S S

S

<220> 22 3> Peptide which specifically binds to SH3 domain with high affinity, thus inhibIting Intracellular signal transmission <400(> 11 L~YS (AU Arg Pro Pro Pro Val Pro Asn Pro Asp Tyr Glo Glu Lepu 1 5 10 *see <2 <'211> <21 2> 13>

PIRT

Ar t i f cialI Seqijence <220> Pepltidv which spceificoilly binds to SH3 domain with high affinity, thuLS inhii t Ing intracci lular signal transmission <c22 2 <223> phosphorylal ion <400> 1 Lys Gbu Arg Pro Pro Pro ij Pro Asn Pro Asp Tyr (flu Glu l.e'ij <M 1031 <2i(1> 11 <212> MCT <_21I> Ar tif i ciai Sequence <220> <22)3 Ly S G ILI Comparative ipILide 1 3 Ala Pro Ala Pro Val Ala Asn Pro Asp 5 0*

Claims (13)

1. A peptide having the amino acid sequence represented by the following formula KXIX 2 X 3 PX 4 X 5 PPXPX (I) Wherein, K is Lys; P is Pro; X, is Glu, Arg, Asp or Lys; X 2 is Arg, Lys, Pro, Leu or lie; X 3 X 4 and X 5 are, identical or different from each other, independently Pro, Met, Val, Trp, Phe, Lie or Leu; X 6 is Asn, Gin, Arg or Lys; and X 7 is Asp, Glu, Arg or Lys. Wherein, said peptide binds to SH3 domains for disrupting an intracellular signal transduction mediated by proteins including SH3 domains.

2. The peptide according to Claim 1, wherein one of the amino acid residues may be gi" conjugated to I or 4 amino acid residues, wherein in the case that one residue is conjugated, the amino acid is Tyr, pTyr(Phosphotyrosine), and that four residues are conjugated, the amino acids may be Tyr or pTyr for the first residue, Asp or Glu for the second and third residues, and hydrophobic amino acids such as lie, Leu, Val or Met for the fourth residue.

3. The peptide according to Claim 1 or Claim 2, which is one of SEQ. ID. NO. 1 o: through SEQ. ID. NO. 12.

4. The peptide according to any one of Claim 1 to Claim 3, which has mono- or di- lipids at its N-terminal.

5. The peptide according to Claim 4, wherein said lipid is palmityl group. 5. The peptide according to Claim 4, wherein said lipid is palmityl group. -23 P \OPEA\j:,%A, cIldl20 Ol5 ?1I.S'226085 7 -p-K dc .1p 07 W

6. The peptide according to any one of Claim 1 to Claim 5, wherein the amino acid residues are L-amino acids.

7. The peptide according to any one of Claim 1 to Claim 6, wherein one or more of the amino acid residues are D-amino acids.

8. The peptide according to any one of Claim 1 to Claim 7, wherein one or more of the amino acid residues are hydroxyproline, hydroxylysine, cistine, throxine, norleucine, pyroglutamic acid, or methylated amino acids.

9. The peptide according to any one of Claim 1 to Claim 8, wherein C-terminal of the peptide is in the form of amide, carboxyl or ester.

10. The peptide according to any one of Claim 1 to Claim 9, wherein it is coupled to palmitoyl-palmitoyl-lysine or palmitoyl-palmitoyl-palmitoyl-lysine.

11. A pharmaceutical composition for preventing or treating cancer or immunosuppression-related diseases, which comprises one or more peptides of any one of Claim 1 to Claim 10 as an active ingredient and pharmaceutically acceptable carriers. 15

12. A peptide according to any one of Claim 1 to Claim 10 substantially as hereinbefore described with reference to the examples and/or figures.

13. A pharmaceutical composition according to Claim 11 substantially as hereinbefore described with reference to the examples and/or figures. 20 DATED this 15th day of July, 2004 CytoSys Inc C.. by DAVIES COLLISON CAVE Patent Attorneys for the Applicant(s) **oo -24-